

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

July 16, 2021

Richard S. Kollender President & Chief Financial Officer Strongbridge Biopharma plc 900 Northbrook Drive, Suite 200 Trevose, PA 19053

> Re: Strongbridge Biopharma plc Form 10-K for the fiscal year ended December 31, 2020 Filed March 3, 2021 File No. 001-37569

Dear Mr. Kollender:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences